Research programme: vascular endothelial growth factor - Genix

Drug Profile

Research programme: vascular endothelial growth factor - Genix

Alternative Names: VEGF - Genix

Latest Information Update: 17 Jun 2013

Price : $50

At a glance

  • Originator University of California at San Francisco
  • Developer Genix Therapeutics
  • Class Growth factors
  • Mechanism of Action Vascular endothelial growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 17 Jun 2013 Discontinued - Preclinical for Erectile dysfunction in USA (Parenteral)
  • 13 Jul 2004 Preclinical trials in Erectile dysfunction in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top